BerGenBio narrows R&D to focus on NSCLC and Covid-19; Oral SERDs see another setback as G1 drops program

BerGenBio said it will prioritize its pipeline to focus on first-line non-small cell lung cancer and Covid-19 with its lead drug bemcentinib. That means work in acute myeloid leukemia, MDS and ovarian cancer has been put on pause.

The company said the narrowed R&D work provides the “optimal path towards...

Click to view original post